Clinical Trial Update: Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa [Phase 2]

View source ↗

Summary

Brivekimig is being studied in a Phase 2 trial for moderate to severe hidradenitis suppurativa, with recruitment currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Brivekimig

Snippet

Sponsor: Sanofi | Conditions: Hidradenitis Suppurativa | Phase 2 | Status: RECRUITING